
Candel Therapeutics, Inc. (NASDAQ:CADL – Free Report) – Equities researchers at Brookline Capital Markets issued their FY2027 earnings estimates for shares of Candel Therapeutics in a research report issued to clients and investors on Friday, November 13th. Brookline Capital Markets analyst K. Dolliver anticipates that the company will earn ($1.52) per share for the year. The consensus estimate for Candel Therapeutics’ current full-year earnings is ($1.22) per share.
Candel Therapeutics (NASDAQ:CADL – Get Free Report) last issued its quarterly earnings results on Friday, November 13th. The company reported ($0.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.06.
Get Our Latest Research Report on Candel Therapeutics
Candel Therapeutics Stock Performance
NASDAQ CADL opened at $5.40 on Monday. The company’s fifty day moving average is $9.47 and its two-hundred day moving average is $8.39. Candel Therapeutics has a 52-week low of $4.35 and a 52-week high of $14.00. The company has a debt-to-equity ratio of 0.37, a current ratio of 7.57 and a quick ratio of 7.57. The firm has a market capitalization of $423.63 million, a price-to-earnings ratio of -3.65 and a beta of -0.27.
Institutional Investors Weigh In On Candel Therapeutics
Several institutional investors and hedge funds have recently bought and sold shares of CADL. BlackRock Inc. bought a new position in shares of Candel Therapeutics during the 2nd quarter worth about $51,181,000. Bank of America Corp DE acquired a new stake in shares of Candel Therapeutics during the 2nd quarter valued at about $2,873,000. Wellington Management Group LLP acquired a new stake in shares of Candel Therapeutics during the 2nd quarter valued at about $2,119,000. Bank of New York Mellon Corp acquired a new stake in shares of Candel Therapeutics during the 2nd quarter valued at about $1,975,000. Finally, Janus Henderson Group PLC bought a new stake in Candel Therapeutics in the first quarter valued at about $845,000. Institutional investors own 13.93% of the company’s stock.
Key Stories Impacting Candel Therapeutics
Here are a few of the latest stories about CADL:
- Neutral Sentiment: HC Wainwright maintained its Buy rating and $18 price target, while raising its FY2026 loss estimate. The target is a supportive signal, but the firm’s longer-range forecasts were cut substantially. MarketBeat analyst estimates
- Negative Sentiment: HC Wainwright lowered projected earnings for FY2027 through FY2030, including moving its FY2028 estimate from a profit to a loss. Brookline’s estimates also point to ongoing quarterly losses through 2027, reinforcing concerns about the path to profitability. MarketBeat analyst estimates
- Negative Sentiment: Law firms announced investigations and investor notices following Candel’s delay of its aglatimagene biologics license application (BLA) for prostate cancer to mid-2027. The notices allege potential securities-law issues; they are not findings of wrongdoing. The filing delay had already triggered a sharp selloff, and the legal scrutiny could add uncertainty. SBS Law investigation notice Levi and Korsinsky investigation notice
Candel Therapeutics Company Profile
Candel Therapeutics is a clinical-stage biotechnology company developing viral immunotherapies designed to stimulate the immune system to fight cancer. Its approach uses engineered viruses to trigger immune responses against tumors. The company’s clinical-stage programs include CAN-2409, an adenovirus-based therapy being studied in several solid tumors, and CAN-3110, an oncolytic herpes simplex virus therapy being investigated for recurrent glioblastoma. Based in Needham, Massachusetts, Candel conducts clinical development of its therapies for cancer indications.
Recommended Stories
- Five stocks we like better than Candel Therapeutics
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Candel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Candel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
